Aequus Pharmaceuticals Inc logo

AQS - Aequus Pharmaceuticals Inc Share Price

C$0.095 -0.0  -9.5%

Last Trade - 11/08/20

Micro Cap
Market Cap £4.38m
Enterprise Value £5.50m
Revenue £1.08m
Position in Universe 1813th / 2678
Unlock AQS Revenue
Relative Strength (%)
1m +32.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -47.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.70 1.14 1.41 1.63
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Aequus Pharmaceuticals Inc revenues increased 76% to C$579K. Net loss decreased 44% to C$406K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General administration - Balancing value decrease of 25% to C$237K (expense), Sales and marketing - Balancing value decrease of 11% to C$332K (expense), Management, wages.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


AQS Revenue Unlock AQS Revenue

Net Income

AQS Net Income Unlock AQS Revenue

Normalised EPS

AQS Normalised EPS Unlock AQS Revenue

PE Ratio Range

AQS PE Ratio Range Unlock AQS Revenue

Dividend Yield Range

AQS Dividend Yield Range Unlock AQS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AQS EPS Forecasts Unlock AQS Revenue
Profile Summary

Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 3, 2013
Public Since March 17, 2015
No. of Shareholders: n/a
No. of Employees: 11
Sector Healthcare
Industry Pharmaceuticals
Exchange TSX Venture Exchange
Shares in Issue 80,437,970
Free Float (0.0%)
Eligible for
AQS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for AQS
Upcoming Events for AQS
Frequently Asked Questions for Aequus Pharmaceuticals Inc
What is the Aequus Pharmaceuticals Inc share price?

As of 11/08/20, shares in Aequus Pharmaceuticals Inc are trading at C$0.095, giving the company a market capitalisation of £4.38m. This share price information is delayed by 15 minutes.

How has the Aequus Pharmaceuticals Inc share price performed this year?

Shares in Aequus Pharmaceuticals Inc are currently trading at C$0.095 and the price has moved by -36.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aequus Pharmaceuticals Inc price has moved by -37.54% over the past year.

What are the analyst and broker recommendations for Aequus Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Aequus Pharmaceuticals Inc, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Aequus Pharmaceuticals Inc is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Aequus Pharmaceuticals Inc next release its financial results?

Aequus Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Aequus Pharmaceuticals Inc dividend yield?

Aequus Pharmaceuticals Inc does not currently pay a dividend.

Does Aequus Pharmaceuticals Inc pay a dividend?

Aequus Pharmaceuticals Inc does not currently pay a dividend.

When does Aequus Pharmaceuticals Inc next pay dividends?

Aequus Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Aequus Pharmaceuticals Inc shares?

To buy shares in Aequus Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aequus Pharmaceuticals Inc?

Shares in Aequus Pharmaceuticals Inc are currently trading at C$0.095, giving the company a market capitalisation of £4.38m.

Where are Aequus Pharmaceuticals Inc shares listed? Where are Aequus Pharmaceuticals Inc shares listed?

Here are the trading details for Aequus Pharmaceuticals Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: AQS
What kind of share is Aequus Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Aequus Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aequus Pharmaceuticals Inc share price forecast 2020?

We were not able to load any forecast data for Aequus Pharmaceuticals Inc.

How can I tell whether the Aequus Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aequus Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -13%. At the current price of C$0.095, shares in Aequus Pharmaceuticals Inc are trading at -14.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aequus Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Aequus Pharmaceuticals Inc.

Who are the key directors of Aequus Pharmaceuticals Inc?

Aequus Pharmaceuticals Inc's management team is headed by:

Douglas Janzen - CHM
Anne Stevens - VPR
Rodoula Plakogiannis - DRC
Fotios Plakogiannis - DRC
Christopher Clark - DRC
Jason Flowerday - DRC
Hamed Shahbazi - DRC
Ann Fehr - CFO
Stuart Fowler - DRC
Who are the major shareholders of Aequus Pharmaceuticals Inc?

Here are the top five shareholders of Aequus Pharmaceuticals Inc based on the size of their shareholding:

Next Edge Capital Corp. Hedge Fund
Percentage owned: 8.02% (6.45m shares)
Next Edge Bio-Tech Plus Class Hedge Fund Portfolio
Percentage owned: 8.02% (6.45m shares)
Janzen (Douglas Glen) Individual Investor
Percentage owned: 6.65% (5.35m shares)
Plakogiannis (Rodoula) Individual Investor
Percentage owned: 2.45% (1.97m shares)
Stevens (Anne Michelle) Individual Investor
Percentage owned: % (n/a shares)
Similar to AQS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.